PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy

Summary

This phase II trial tests whether PEA works to relieve the symptoms of chemotherapy-induced peripheral neuropathy in patients with cancer. Chemotherapy-induced peripheral neuropathy refers to a nerve problem that causes pain, numbness, tingling, or muscle weakness in different parts of the body, and is caused by chemotherapy. PEA may be useful against bothersome nerve symptoms.

Timeline

Start

2022-05-16

Primary completion

2024-02-12

Completion

2026-02-28

Outcome

Missed primary endpoint

registry analysis (superiority test); Lower-dose PEA vs Combined Placebo; Mean Difference (Final Values) 2.21 (95% CI -1.33 to 5.74) NCT05246670 ↗

registry analysis (superiority test); Higher-dose PEA vs Combined Placebo; Mean Difference (Final Values) 0.09 (95% CI -5.23 to 5.41) NCT05246670 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Palmidrol	Small molecule	—	Oral

Indications